Using agents such as AZ20 (ATR inhibitor) and ISRIB (inhibitor of eIF2α phosphorylation), this study demonstrates that Chk1 inhibitors are able to prevent tumor-induced bone loss by blocking tumor growth as well as bone resorption. Here, ATR is linked to neoplasm.